Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Sep 16;15(12):3028–3039. doi: 10.1158/1535-7163.MCT-16-0366

Fig. 1. HER2 and EGFR phosphorylate FAK Y397 independently of FAK-kinase activity.

Fig. 1

Immunoblots showing phosphorylation of FAK and downstream molecules in HER2+ breast cancer cells (A) MDA-MB-453 and (C) SkBr3, as well as EGFR+ lung cancer cells (B) H292 and (D) A549. Cancer cells were serum-starved overnight followed by drug treatment with FAK-kinase inhibitor (defactinib, PF-228, PF-271) or HER2/EGFR inhibitor (Lapatinib) for 1 hour and stimulated with either Heregulin-β1 (HRG) or Epidermal Growth Factor (EGF) for 30 min. Images shown are representative of three independent experiments. Densitometry and statistical analysis is found in Supplementary Fig. S1, S2, and Table S1.